866-997-4948(US-Canada Toll Free)

Chikungunya Fever-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 103 Pages

Chikungunya Fever-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever-Pipeline Review, H2 2017, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 14 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 5 molecules, respectively.

Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Chikungunya Fever-Overview 8
Chikungunya Fever-Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Chikungunya Fever-Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Chikungunya Fever-Companies Involved in Therapeutics Development 25
Abivax SA 25
Arno Therapeutics Inc 25
Bharat Biotech International Ltd 25
Ennaid Therapeutics LLC 26
Etubics Corp 26
Hawaii Biotech Inc 27
Indian Immunologicals Ltd 27
Inovio Pharmaceuticals Inc 27
Integral Molecular Inc 28
Integrated BioTherapeutics Inc 28
Moderna Therapeutics Inc 28
Mymetics Corp 29
Nanotherapeutics Inc 29
Paradigm Biopharmaceuticals Ltd 30
PaxVax Inc 30
Profectus BioSciences Inc 30
Shionogi & Co Ltd 31
Takeda Pharmaceutical Co Ltd 31
Themis Bioscience GmbH 32
Valneva SE 32
Vaxart Inc 33
Chikungunya Fever-Drug Profiles 34
(chikungunya + Zika) (bivalent) vaccine-Drug Profile 34
ABX-311-Drug Profile 35
AR-12-Drug Profile 36
BBV-87-Drug Profile 39
chikungunya (viral like particles) vaccine-Drug Profile 40
chikungunya (virus like particle) vaccine-Drug Profile 41
chikungunya vaccine-Drug Profile 42
chikungunya vaccine-Drug Profile 44
chikungunya vaccine-Drug Profile 45
chikungunya vaccine-Drug Profile 46
chikungunya vaccine-Drug Profile 47
chikungunya vaccine-Drug Profile 48
chikungunya vaccine-Drug Profile 49
chikungunya vaccine-Drug Profile 50
chikungunya vaccine-Drug Profile 51
chikungunya vaccine-Drug Profile 52
chikungunya vaccine-Drug Profile 53
chikungunya vaccine-Drug Profile 54
chikungunya vaccine-Drug Profile 55
chikungunya vaccine-Drug Profile 56
Gene Therapy for Chikungunya-Drug Profile 57
HSRx-431-Drug Profile 58
IMCKV-063-Drug Profile 59
Monoclonal Antibodies for Chikungunya-Drug Profile 60
Monoclonal Antibodies for Equine Encephalitis and Chikungunya-Drug Profile 61
Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya-Drug Profile 62
mRNA-1388-Drug Profile 63
MV-CHIK-Drug Profile 64
pentosan polysulfate sodium-Drug Profile 67
Peptides for Infectious Diseases-Drug Profile 71
SCV-305-Drug Profile 72
Small Molecule to Inhibit NS2 and NS3 for Chikungunya-Drug Profile 73
Small Molecule to Inhibit NS4 for Chikungunya Fever-Drug Profile 74
Small Molecules for Chikungunya-Drug Profile 75
Small Molecules for Chikungunya-Drug Profile 76
Small Molecules for Chikungunya Fever-Drug Profile 77
Small Molecules for Chikungunya Fever-Drug Profile 78
Small Molecules for Infectious Disease-Drug Profile 79
SVIR-001-Drug Profile 80
Synthetic Peptides for Chikungunya-Drug Profile 81
TAK-507-Drug Profile 82
Tatbeclin-1-Drug Profile 83
VLA-1553-Drug Profile 84
Chikungunya Fever-Dormant Projects 85
Chikungunya Fever-Product Development Milestones 86
Featured News & Press Releases 86
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

List of Tables
Number of Products under Development for Chikungunya Fever, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Chikungunya Fever-Pipeline by Abivax SA, H2 2017
Chikungunya Fever-Pipeline by Arno Therapeutics Inc, H2 2017
Chikungunya Fever-Pipeline by Bharat Biotech International Ltd, H2 2017
Chikungunya Fever-Pipeline by Ennaid Therapeutics LLC, H2 2017
Chikungunya Fever-Pipeline by Etubics Corp, H2 2017
Chikungunya Fever-Pipeline by Hawaii Biotech Inc, H2 2017
Chikungunya Fever-Pipeline by Indian Immunologicals Ltd, H2 2017
Chikungunya Fever-Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Chikungunya Fever-Pipeline by Integral Molecular Inc, H2 2017
Chikungunya Fever-Pipeline by Integrated BioTherapeutics Inc, H2 2017
Chikungunya Fever-Pipeline by Moderna Therapeutics Inc, H2 2017
Chikungunya Fever-Pipeline by Mymetics Corp, H2 2017
Chikungunya Fever-Pipeline by Nanotherapeutics Inc, H2 2017
Chikungunya Fever-Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
Chikungunya Fever-Pipeline by PaxVax Inc, H2 2017
Chikungunya Fever-Pipeline by Profectus BioSciences Inc, H2 2017
Chikungunya Fever-Pipeline by Shionogi & Co Ltd, H2 2017
Chikungunya Fever-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Chikungunya Fever-Pipeline by Themis Bioscience GmbH, H2 2017
Chikungunya Fever-Pipeline by Valneva SE, H2 2017
Chikungunya Fever-Pipeline by Vaxart Inc, H2 2017
Chikungunya Fever-Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Chikungunya Fever, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *